Cargando…

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia

Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Jong Hyung, Park, Jeong Ah, Kim, Eun Kyung, Kang, Hyoung Jin, Shin, Hee Young, Ahn, Hyo Seop
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672129/ https://www.ncbi.nlm.nih.gov/pubmed/19399271 http://dx.doi.org/10.3346/jkms.2009.24.2.281

Ejemplares similares

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
por: Koh, Kyung-Nam, et al.
Publicado: (2017)

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia
por: Lee, Se Ryeon, et al.
Publicado: (2009)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
por: Shah, Gaurav, et al.
Publicado: (2019)

Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2018)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia
por: Sang, Wei, et al.
Publicado: (2016)

FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Sung-Liang, et al.
Publicado: (2020)

T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
por: Elreda, Lauren, et al.
Publicado: (2014)

Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia()
por: Bradstock, Kenneth F., et al.
Publicado: (2016)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission
por: Bandyopadhyay, Sabyasachi, et al.
Publicado: (2010)

TP53 alterations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Chih‐Hsiang, et al.
Publicado: (2019)

Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents
por: Kim, Hyery, et al.
Publicado: (2014)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia
por: Pan, Liyan, et al.
Publicado: (2017)

Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia
por: Zhang, Rongrong, et al.
Publicado: (2020)

Relapsed Childhood Acute Lymphoblastic Leukemia: A Single-Institution Experience
por: Tuong, Pham Nguyen, et al.
Publicado: (2020)

Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Gasic, Vladimir, et al.
Publicado: (2019)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL)
por: Mejía-Aranguré, Eréndira, et al.
Publicado: (2022)

Meta-analysis of gene expression in relapsed childhood B-acute lymphoblastic leukemia
por: Chow, Yock-Ping, et al.
Publicado: (2017)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

FLAG Regimen with or without Idarubicin in Children with Relapsed/Refractory Acute Leukemia: Experience from a Turkish Pediatric Hematology Center
por: Yılmaz Bengoa, Şebnem, et al.
Publicado: (2017)

Treatment outcome of doxorubicin versus idarubicin in adult acute myeloid leukemia
por: Sherif, Hemat Afifi, et al.
Publicado: (2021)

Complete remission with romidepsin in a patient with T‐cell acute lymphoblastic leukemia refractory to induction hyper‐CVAD
por: Brunvand, Mark W., et al.
Publicado: (2017)

Confocal microscopy of idarubicin localisation.
por: Manfait, M., et al.
Publicado: (1997)

Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia: An Analysis of Day-One Versus Day-Eight Lumbar Punctures in Remission Induction Therapy
por: Arshad, Uzma, et al.
Publicado: (2021)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Relapse specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
por: Meyer, Julia A., et al.
Publicado: (2013)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
por: Weng, Jianyu, et al.
Publicado: (2018)

Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy
por: Hu, Zhongbo, et al.
Publicado: (2021)

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2022)

Spontaneous remission of acute lymphoblastic leukemia: A case report
por: Höres, Timm, et al.
Publicado: (2018)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Confocal microscopy of idarubicin localisation - reply
por: Duffy, P, et al.
Publicado: (1997)

Health-Related Quality of Life in Long-Term Survivors of Relapsed Childhood Acute Lymphoblastic Leukemia
por: Essig, Stefan, et al.
Publicado: (2012)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
por: Zheng, Qingqing, et al.
Publicado: (2020)

Relapsed Childhood Acute Lymphoblastic Leukemia: Experience from a Single Tertiary Center in Thailand
por: Chotsampancharoen, Thirachit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g7igqgfka3cc29lsmevfdcdqja